Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib

Annals of Oncology

Volumn 20, Issue 9, 2009, Pages 1606-1607

  Cathomas, Richard ^a   von Moos, R ^a  

^a KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CA 15-3 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN; LAPATINIB; STEROID; TRASTUZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER REGRESSION; CASE REPORT; DISEASE COURSE; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER INJURY; LYMPH NODE METASTASIS; METASTASIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 69849090266     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp370     Document Type: Article

References (5)

1. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357: 580-587.
2. Cathomas R, Goldhirsch A, von Moos R. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357: 1870-1871.
3. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast. N Engl J Med 2006; 355: 2733-2743.
4. GlaxoSimithKline (Study Numbers EGF20002, 20003, 20004, 20008) http://www.gsk-clinicalstudyregister.com (16 July 2009, date last accessed).
5. Johnston S, Pegram M, Pippen J et al. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive metastatic breast cancer: First results from the EGF300008 trial. In San Antonio Breast Cancer Symposium 2008; (Abstr 46).